Answers are grounded in this paper and cite their sources.
In Illumina next-generation sequencing, target DNA fragments are ligated to adapters containing chemically modified uracil bases, which are subsequently cleaved by uracil-specific excision reagent (USER) to generate the Y-shaped structure essential for downstream sequencing. Herein, we employed the trans-cleaving F-8 DNAzyme as a starting scaffold (DNAzyme reagent) and performed site-directed mutagenesis within its catalytic core. By combining highly active mutations, we identified the variant F-85A6A, which exhibited the highest cleavage yield and demonstrated superior adapter-cleavage efficiency relative to USER, underscoring its potential as a cost-effective USER substitute. We then integrated the catalytic core of the F-8 DNAzyme into the Illumina adapter architecture to design F-8H1. Sequential optimization of the binding arm length and further mutagenesis yielded the highly active mutant H6-13A42A. The 5′ end of H6-13A42A was modified with a phosphate group to construct a complete self-cleaving adapter. In a simulated dual-adapter sequencing structure, the self-cleaving adapter achieved cleavage efficiency comparable to that of USER-treated Illumina adapters while reducing reagent costs by 97.5%, thereby offering an economical molecular tool for advancing DNA sequencing technology.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: